Your browser doesn't support javascript.
loading
Uptake and 4-week quit rates from an opt-out co-located smoking cessation service delivered alongside community-based low-dose computed tomography screening within the Yorkshire Lung Screening Trial.
Murray, Rachael L; Alexandris, Panos; Baldwin, David; Brain, Kate; Britton, John; Crosbie, Philip A J; Gabe, Rhian; Lewis, Sarah; Parrott, Steve; Quaife, Samantha L; Tam, Hui Zhen; Wu, Qi; Beeken, Rebecca; Copeland, Harriet; Eckert, Claire; Hancock, Neil; Lindop, Jason; McCutchan, Grace; Marshall, Catriona; Neal, Richard D; Rogerson, Suzanne; Quinn Scoggins, Harriet D; Simmonds, Irene; Thorley, Rebecca; Callister, Matthew E.
Afiliação
  • Murray RL; School of Medicine, University of Nottingham, Nottingham, UK rachael.murray@nottingham.ac.uk.
  • Alexandris P; Centre for Prevention, Detection and Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
  • Baldwin D; Department of Respiratory Medicine, Nottingham University Hospitals NHS Trust, Nottingham, UK.
  • Brain K; Division of Population Medicine, Cardiff University, Cardiff, UK.
  • Britton J; School of Medicine, University of Nottingham, Nottingham, UK.
  • Crosbie PAJ; Division of Infection, Immunity and Respiratory Medicine, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
  • Gabe R; Barts Clinical Trials Unit, Centre for Evaluation and Methods, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
  • Lewis S; School of Medicine, University of Nottingham, Nottingham, UK.
  • Parrott S; York Trials Unit, Department of Health Sciences, University of York, York, UK.
  • Quaife SL; Centre for Prevention, Detection and Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
  • Tam HZ; Barts Clinical Trials Unit, Centre for Evaluation and Methods, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
  • Wu Q; York Trials Unit, Department of Health Sciences, University of York, York, UK.
  • Beeken R; Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
  • Copeland H; Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
  • Eckert C; Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
  • Hancock N; Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
  • Lindop J; Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • McCutchan G; Division of Population Medicine, Cardiff University, Cardiff, UK.
  • Marshall C; Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
  • Neal RD; College of Medicine and Health, University of Exeter, Exeter, UK.
  • Rogerson S; Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • Quinn Scoggins HD; PRIME Centre Wales, Division of Population Medicine, School of Medicine, Cardiff University, Cardiff, UK.
  • Simmonds I; Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
  • Thorley R; School of Medicine, University of Nottingham, Nottingham, UK.
  • Callister ME; Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
Eur Respir J ; 63(4)2024 Apr.
Article em En | MEDLINE | ID: mdl-38636970
ABSTRACT

BACKGROUND:

Up to 50% of those attending for low-dose computed tomography screening for lung cancer continue to smoke and co-delivery of smoking cessation services alongside screening may maximise clinical benefit. Here we present data from an opt-out co-located smoking cessation service delivered alongside the Yorkshire Lung Screening Trial (YLST).

METHODS:

Eligible YLST participants were offered an immediate consultation with a smoking cessation practitioner (SCP) at their screening visit with ongoing smoking cessation support over subsequent weeks.

RESULTS:

Of 2150 eligible participants, 1905 (89%) accepted the offer of an SCP consultation during their initial visit, with 1609 (75%) receiving ongoing smoking cessation support over subsequent weeks. Uptake of ongoing support was not associated with age, ethnicity, deprivation or educational level in multivariable analyses, although men were less likely to engage (adjusted OR (ORadj) 0.71, 95% CI 0.56-0.89). Uptake was higher in those with higher nicotine dependency, motivation to stop smoking and self-efficacy for quitting. Overall, 323 participants self-reported quitting at 4 weeks (15.0% of the eligible population); 266 were validated by exhaled carbon monoxide (12.4%). Multivariable analyses of eligible smokers suggested 4-week quitting was more likely in men (ORadj 1.43, 95% CI 1.11-1.84), those with higher motivation to quit and previous quit attempts, while those with a stronger smoking habit in terms of cigarettes per day were less likely to quit.

CONCLUSIONS:

There was high uptake for co-located opt-out smoking cessation support across a wide range of participant demographics. Protected funding for integrated smoking cessation services should be considered to maximise programme equity and benefit.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tabagismo / Abandono do Hábito de Fumar Idioma: En Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tabagismo / Abandono do Hábito de Fumar Idioma: En Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Reino Unido